Börse:
38,663€
0,28%
Echtzeit-Aktienkurs Emergent Biosolutions
Bid:
38,375€
Ask:
38,950€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 1,98 Mrd. EUR (51,20 Mio. x 38,663€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 2,91 | 3,21 | 3,41 | 2,53 |
| KGV | 27,42 | 34,21 | 22,61 | 31,69 |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Emergent Biosolutions Aktie
Börsenkurse Emergent Biosolutions
| Börse Stuttgart | 38,325€ | 0 | 39,000€ | 0 | 38,663€ | 1,18% |
| Dollar Indikation | 42,739$ | 0 | 43,304$ | 0 | 43,022$ | -0,21% |
| Lang & Schwarz | 38,340€ | 52 | 38,830€ | 52 | 38,585€ | 0,00% |
| Euro Indikation | 38,375€ | 0 | 38,950€ | 0 | 38,663€ | 0,28% |
| Tradegate | 38,375€ | 79 | 38,950€ | 77 | 38,663€ | 0,10% |
Fundamentaldaten der Emergent Biosolutions Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 782,40 Mio. | 81,50 Mio. | 62,70 Mio. | 1,22 | 0,00% | 31,69 | 2,53 |
| 2017 | 560,87 Mio. | 118,63 Mio. | 82,59 Mio. | 1,71 | 0,00% | 22,61 | 3,41 |
| 2016 | 488,78 Mio. | 99,22 Mio. | 51,78 Mio. | 1,13 | 0,00% | 34,21 | 3,21 |
| 2015 | 522,79 Mio. | 89,77 Mio. | 62,87 Mio. | 1,41 | 0,00% | 27,42 | 2,91 |
| 2014 | 450,14 Mio. | 53,06 Mio. | 36,74 Mio. | 0,88 | 0,00% | 43,93 | 3,24 |
Profil der Emergent Biosolutions Aktie
Emergent BioSolutions Inc. is a global specialty biopharmaceutical company focused on the development, manufacture and distribution of a portfolio of medical countermeasures (vaccines, therapeutics and other novel products) and related services for civilian and military populations that address intentional and naturally emerging public health threats, specifically Chemical, Biological, Radiological, Nuclear and Explosive, or CBRNE, threats as well as emerging infectious diseases. The company operations include manufacturing, regulatory affairs, quality assurance, quality control, international sales and marketing and domestic government affairs in support of its portfolio of marketed products, as well as product development and manufacturing infrastructure in support of its portfolio of investigational stage product candidates. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen